Woman With Down Syndrome Had Alzheimer's Without Dementia in Surprise Case
Though the reasons aren't well understood, having an extra copy of chromosome 21 seems to hasten the neurodegeneration that puts individuals at risk of developing Alzheimer's disease.
For the last decade of her life, and beyond, a US woman with Down syndrome mystified researchers by showing all of the physical signs of having Alzheimer's with none of the expected symptoms.
The team behind her recent case study hopes that by understanding the nature of the woman's unusual situation, researchers might gain deeper insights into the manifestation of dementia.
"If we can identify the genetic underpinnings or lifestyle factors that allowed her brain to function well despite the pathology, we may uncover strategies that could benefit others," says University of California, Irvine neuroscientist Elizabeth Head.
"This study shows how just one person's participation in research can lead to profound discoveries."
While it isn't hard for specialists to find older cognitively healthy individuals with Alzheimer's pathology, it's less common to find people with Down syndrome who aren't affected by their neurodegeneration.
Most develop early signs of dementia as they approach their mid-50s, with those in their 60s experiencing a 90 percent chance of developing the clinical features of either mild cognitive decline or full dementia.
The Alzheimer Biomarker Consortium–Down Syndrome was established in 2015 to better understand the links between the two conditions by examining the physical markers of Alzheimer's among people born with trisomy 21.
By the time she was enrolled in the consortium, the remarkable patient who showed no signs of cognitive decline in spite of being in her sixties had already participated in two separate longitudinal studies funded by the US National Institutes of Health, providing a wealth of clinical and psychological data.
Decades of tests had shown that she had both Down syndrome and an intermediate level of Alzheimer's. Physical examinations demonstrated elevated levels of amyloid in her brain, signature ratios of proteins in her spinal fluid, and critical changes in her neurological wiring synonymous with dementia.
Yet a battery of psychological tests indicated the woman's mind had remained relatively sharp for the entire period of her testing. In her daily life, the woman did her cooking and shopping, with no outward signs of change in behavior or social interactions prior to her passing.
"Before she passed away, all the clinical assessments in our years of studying her indicated that she was cognitively stable, which is why this case is so fascinating," says consortium investigator Jr-Jiun Liou, a neurologist with the University of Pittsburgh.
"Despite her brain's pathology indicating Alzheimer's, we think that her cognitive stability could have been attributed to her high education level or underlying genetic factors."
Though her IQ was below average, the woman had attained a private education through childhood and into adolescence at a school that had been licensed to teach students with intellectual disabilities.
Physiologically, there were various factors that could have also given her brain a margin of resistance against Alzheimer's degeneration, including a potential 'reserve' in extra brain tissue, and genes that helped cope with accumulations of damaged proteins.
There is also an unanswered question of the nature of her trisomy. In some cases, those with characteristics of Down syndrome have a form of mosaicism, where some cells have just the typical pair of chromosome 21.
Should that be the case here, it's possible the incomplete spread of a third chromosome 21 through the body could be significant.
On its own, the study raises some questions.
While this woman's case is unusual, combined with other investigations of similar cases, her remarkable story could one day help others with Alzheimer's remain cognitively strong well into old age.
This research was published in Alzheimer's & Dementia.
3 Out of 5 Adults Will Be Classified Overweight by 2050, Study Finds
Australian Man Whose Blood Donations Saved Millions Dies Age 88
Brain Autopsies Reveal a Potential Culprit Behind Alzheimer's
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
2 hours ago
- Epoch Times
Scientists Accidentally Discover Laser-Free LASIK Alternative
A chemistry professor trying to heat cartilage with electricity made a mistake that could change eye surgery. Michael Hill at Occidental College accidentally used too little current in his experiment—and stumbled upon a discovery that might replace LASIK with a gentler treatment that reshapes corneas without ever cutting the eye. The discovery may offer hope for the millions of people living with poor vision who want an alternative to glasses and contact lenses but are wary of LASIK's risks. While laser eye surgery is generally successful, it involves cutting into the eye and can cause complications including dry eyes, vision problems, and in rare cases, severe side effects. Happy Accident Behind the Discovery The breakthrough happened entirely by chance when Hill and his collaborator, Dr. Brian Wong, a professor of otolaryngology-head and neck surgery at the University of California–Irvine, were frustrated with their attempts to reshape cartilage using lasers.
Yahoo
5 hours ago
- Yahoo
Cholesterol Isn't Just About Heart Health—It May Be the Missing Link In Alzheimer's, Says New Study
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new study suggests that there's a link between how well you move cholesterol to the neurons in your brain and Alzheimer's disease. This factor is connected to the APOE4 genetic variant, which significantly increases your risk of developing the disease. Here's what to know and what this means for Alzheimer's research. Alzheimer's disease sparks a cascade of changes throughout the body that lead to a slew of debilitating symptoms. But there's one surprising biological change that researchers are just starting to uncover, thanks to a new study. The study, which was published in the Journal of Lipid Research, found that people with Alzheimer's disease experience a breakdown in the ability to shuttle cholesterol to the neurons in their brain, and that this symptom is linked to a certain genetic variant called APOE4, which carries a known risk for Alzheimer's. This biological discovery could potentially pave the way for a better understanding of the disease and even future disease prevention methods. Here's what you need to know about the science so far, with input from a neurologist. Meet the expert: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA. What did the researchers find? For the study, researchers analyzed the cerebrospinal fluid (the biological liquid that surrounds and cushions the brain and spinal cord) from 10 patients with Alzheimer's disease and compared it to the cerebrospinal fluid of 10 people who did not have the condition. They discovered that lipoproteins (round particles made of fat and protein) in the cerebrospinal fluid of Alzheimer's patients were less effective at delivering cholesterol to neurons, or nerve cells, which are responsible for transmitting information from the brain throughout the body. What is cholesterol? Cholesterol is an essential, waxy, fat-like molecule that your body needs for good health, according to the National Heart Lung and Blood Institute (NHLBI). Cholesterol is carried around your body by two types of lipoproteins: low-density lipoproteins (a.k.a. LDL or 'bad' cholesterol) and high-density lipoproteins (a.k.a. HDL or 'good' cholesterol). High levels of LDL cholesterol can cause a buildup of fatty deposits called plaque in your arteries, raising the risk of heart attack, stroke, and other health complications, per the NHLBI. But high levels of good HDL cholesterol may lower the risk for certain health issues. Why is it important for brain function? While it has a bad rap in the health world, cholesterol is actually really important for your proper brain function. Your brain is the most cholesterol-rich organ in your body. Specifically, cholesterol helps make up cell membranes, including those in nerve cells, and plays a crucial role in your neurons' ability to "talk" to each other and transmit information. When cholesterol levels are out of balance, it can impact that transmission of essential information between nerve cells, leading to cognitive issues that are seen with neurodegenerative diseases like Alzheimer's disease. Cholesterol is also a building block for steroid hormones, which support brain function. However, that doesn't mean more cholesterol is always good for your brain. High levels of LDL cholesterol are usually considered a modifiable risk factor for ischemic stroke, or 'clogged pipes' in the brain, explains Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. 'There is less research and understanding on the possible benefits of cholesterol found in spinal fluid including HDL, which we classically identify as the 'good cholesterol,'' Dr. Segil says. 'We know high levels of certain types of cholesterol cause strokes and we are less clear in the year 2025 about the benefits of cholesterol in brain function.' How does this link back to Alzheimer's? This particular study noted that cholesterol found in lipoproteins were different in patients with Alzheimer's disease, but Dr. Segil says that there is a 'complicated' relationship between lipids and protein in the brain. 'Some researchers continue to assign memory loss symptoms in patients with Alzheimer's due to abnormal brain protein levels and this paper noted lipid brain levels may also be abnormal,' he says. Dr. Segil points out that neurologists commonly prescribe medications called statins to lower levels of cholesterol and the risk of stroke. Lowering levels of LDL cholesterol can decrease the risk of developing certain type of dementia, including vascular dementia, he says. But it's not clear if it may do more. 'Further research will determine if lowering your cholesterol will result in lower chances of getting Alzheimer's dementia,' he says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals Solve the daily Crossword
Yahoo
5 hours ago
- Yahoo
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ('Anavex' or the 'Company') (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported a peer-reviewed publication in the journal Neuroscience Letters, titled 'Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer's disease model.'1 This study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury suggesting that blarcamesine is an attractive candidate for Alzheimer's disease pharmacological prevention. 'This preclinical study is exciting since it clearly demonstrates a preventative effect of blarcamesine in Alzheimer's pathology and potentially might be able to prevent onset of Alzheimer's disease in healthy individuals,' said Tangui Maurice, PhD, Research Director at University of Montpellier, France and author of the publication. 'These findings support the future direction of clinical trials with the objective of addressing blarcamesine's potential as a safe and effective pharmacologic agent — applied as convenient once-daily oral pill — for the prevention of Alzheimer's disease.' While placebo-controlled mice developed significant amyloid toxicity in the brains after the toxic Aβ25-35 peptide injection, in animals pre-treated with blarcamesine, significant protection was observed with less vulnerability to Aβ25-35-induced oxidative stress and less vulnerability to develop learning and memory deficits. The mechanistic confirmation that blarcamesine particularly restores impaired autophagy through SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular level was previously established both in vitro and in vivo. Specifically, blarcamesine's studies demonstrated effect of enhanced autophagic flux in human cells and in C. elegans as well as increased proteostasis capacity and ability to promote autophagosome biogenesis, autophagic cargo reception, and lysosome fusion.2 SIGMAR1 has emerged as a key therapeutic target in the treatment of neurodegenerative disorders. Its activation enhances autophagy, facilitating the degradation of amyloid-beta precursor protein (APP) and helping to normalize Aβ production.3 Beyond its role in amyloid regulation, SIGMAR1 activation supports neurogenesis, mitigates oxidative stress by reducing reactive oxygen species (ROS), suppresses neuroinflammatory responses, and alleviates Aβ-induced toxicity. It also plays a critical role in maintaining endoplasmic reticulum (ER) integrity and modulating intracellular calcium signaling.4 Collectively, these effects contribute to the restoration of cellular homeostasis, rebalancing neural function, and promoting neuroplasticity.5 'The findings in this publication further support the potential beneficial effect of blarcamesine in Alzheimer's disease prevention. With once daily oral blarcamesine administration and hence retaining autophagy strength through upstream SIGMAR1 activation, the downstream potentially pathological manifestations of Amyloid beta might be prevented,' said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. The paper can be accessed online at: This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Alzheimer's Disease Alzheimer's disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. An estimated 7.2 million Americans currently have Alzheimer's dementia. Alzheimer's is the most common cause of dementia among older adults and is estimated to rank as the third leading cause of death for older people in the United States, just behind heart disease and cancer. In 2020, Alzheimer's and other dementias cost the nation approximately $781 billion. By 2050, these costs could rise as high as $1.1 trillion.6 There are currently over 50 million people living with dementia around the world, with numbers expected to increase to nearly 152 million by 2050.7 Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case every 3 seconds, and a significant increase in the caregiving burden placed on society and families.8 About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information:Anavex Life Sciences & Business DevelopmentToll-free: 1-844-689-3939Email: info@ Investors:Andrew J. BarwickiInvestor RelationsTel: 516-662-9461Email: andrew@ ________________________1 Maurice, Tangui. 'Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer's disease model.' Neuroscience letters, 138349. Aug. 2025.2 Christ, M G et al. 'Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo.' Cells vol. 8,3 211. 2 Mar. 2019.3 Jaeger PA, Pickford F, Sun C-H, et al. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PloS one. 2010;5(6):e11102.4 Nguyen L, Lucke-Wold BP, Mookerjee SA, et al. Role of sigma-1 receptors in neurodegenerative diseases. Journal of pharmacological sciences. 2015;127(1):17-29; Moriguchi S, Shinoda Y, Yamamoto Y, et al. Stimulation of the sigma-1 receptor by DHEA enhances synaptic efficacy and neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice. PloS one. 2013;8(4):e60863-e60863; Rosen DA, Seki SM, Fernández-Castañeda A, et al. Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Translational Medicine. 2019;11(478):eaau5266; Maurice T, Volle J-N, Strehaiano M, et al. Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer's disease by positive modulation of σ1 receptors. Pharmacological research. 2019;144:315-330.5 Advances in Experimental Medicine and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets.6 Alzheimer's Disease International. World Alzheimer Report 2019. AARP. 2020 Report: Caregiving in the U.S. in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
